Clinical trials: Hepatic Neoplasm
Cancer
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of intravenous VEGF Trap in treating…
- Trial name
- NCT00083213
- Testing
- ziv-aflibercept
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Regeneron Pharmaceuticals
Thrombocytopenia
Treatment of Avatrombopag for Thrombocytopenia in Patients Undergoing Selective Resection of Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world, accounting for the second leading cause of cancer death in China.Surgical treatment of hepatocellular carcinoma is the most important means…
- Trial name
- NCT05087459
- Testing
- Avatrombopag
- Where
- China
- Volunteers
- 141 people
- Sponsor
- Shanghai Zhongshan Hospital
Radiotherapy
Adaptative MR-Guided Stereotactic Body Radiotherapy of Liver Tumors
Hepatic metastases are common in solid cancers (up to 30% of patients with colorectal cancer and up to 50% of patients during their follow-up).
- Trial name
- RASTAF (NCT04242342)
- Testing
- Adaptative MR-Guided Stereotactic Body Radiotherapy
- Where
- France
- Volunteers
- 46 people
- Sponsor
- Centre Georges Francois Leclerc
Hepatic Neoplasm
Scandinavian Cohort Study for Optimal Use of Portal Vein Embolization
Several aspects on the use of portal vein embolization (PVE) are poorly studied and todays recommendations are based on low-grade evidence.
- Trial name
- NCT04182386
- Testing
- Portal vein embolization
- Where
- Sweden
- Volunteers
- 300 people
- Sponsor
- Karolinska University Hospital
Hepatic Neoplasm Malignant
Oxaliplatin and Capecitabine on Top of Sorafenib Versus Sorafenib Alone in Advanced Hepatocellular Carcinoma Patients
Primary Objective: To evaluate the efficacy of SECOX regimen by adding oxaliplatin plus capecitabine to sorafenib versus sorafenib alone as palliative treatment for unresectable HCC patients to prolong overall survival (OS) for…
- Trial name
- SECOX (NCT01245582)
- Testing
- oxaliplatin (SR96669), capecitabine, sorafenib
- Sponsor
- Sanofi
Hepatocellular Carcinoma
Carbon Ion Radiotherapy for the Treatment of Chinese Hepatocellular Carcinoma
The aim of this research project is to assess the feasibility and safety of carbon-ion radiotherapy for the treatment of localized Chinese hepatocellular carcinoma
- Trial name
- NCT02802124
- Testing
- carbon-ion radiotherapy for tumor away from GI, carbon-ion radiotherapy for tumor adjacent to GI
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Proton and Heavy Ion Center
Hepatocellular Carcinoma
Impact of Preoperative Serum Albumin Level on Postoperative Outcomes in Chinese HCC Patients Treated With Surgery
This is an observational and retrospective cohort study to evaluate the impact of the preoperative serum albumin concentration on postoperative outcomes among hepatocellular carcinoma (HCC) patients who received hepatectomy or…
- Trial name
- REAL (NCT05970159)
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Shanghai Zhongshan Hospital
Liver Neoplasm, Colorectal Cancer Metastatic
DEBIRI Plus Chemotherapy vs. Chemotherapy Alone in Colorectal Cancer Liver Metastases
A total of 116 patients who meet the inclusion criteria and are chemotherapy-naïve for their metastatic disease, will be randomly assigned to either the treatment group (DEBIRI plus systemic chemotherapy) or the control group…
- Trial name
- CLEAR-DEBIRI (NCT06555003)
- Testing
- Drug-Eluting Embolic Bead, Chemotherapy drug
- Where
- Iran
- Volunteers
- 116 people
- Sponsor
- Tehran University of Medical Sciences
Liver Diseases, COVID19
COVID19-FOIE National Observatory
Background: The COVID19 and liver relationships are very rare. The preliminary Chinese data indicate that 2-11% of patients treated for COVID19 had an underlying chronic liver disease.
- Trial name
- NCT04375670
- Where
- France
- Volunteers
- 1,132 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Carcinoma, Hepatocellular, Liver Neoplasms
Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors
The purpose of this study is to provide supervised access to treatment with TheraSphere® to eligible patients with primary and metastatic cancer and evaluate response to treatment, survival and toxicity.
- Trial name
- NCT00493883
- Testing
- yttrium Y 90 microspheres (TheraSphere®)
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Southwestern Regional Medical Center
Hepatocellular Carcinoma Non-resectable
Lenvatinib Plus DEB-TACE With/Without FOLFOX-HAIC for Large HCC With PVTT
This multicenter retrospective study evaluated consecutive patients with large HCC and PVTT who received lenvatinib plus DEB-TACE with/without FOLFOX-HAIC between July 2019 and June 2021.
- Trial name
- NCT06265883
- Testing
- Len+DEB-TACE+HAIC, Len+DEB-TACE
- Where
- China
- Volunteers
- 205 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma, Radiation Exposure
Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment
The objective of this study is to examine critical aspects of radiation exposure, dose delivery, and systemic yttrium-90 (Y90) exposure related to the infusion of Y90 microspheres for treatment of hepatocellular carcinoma (HCC)…
- Trial name
- NCT03686709
- Testing
- Post therapy PET/CT Imaging
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Tennessee
Hepatocellular Carcinoma
TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC
The purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) and molecular target therapies in patients with advanced-stage…
- Trial name
- CHANCE2201 (NCT05332821)
- Testing
- PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE
- Where
- 2 sites in China
- Volunteers
- 1,244 people
- Sponsor
- Zhongda Hospital
Congenital Portosystemic Shunt, CPSS (Congenital Portosystemic Shunt)
International Registry of Congenital Portosystemic Shunt (IRCPSS)
Congenital Portosystemic Shunt (CPSS) is a rare condition important by the multiplicity and severity of associated complications.
- Trial name
- IRCPSS (NCT06041906)
- Testing
- Shunt Closure
- Where
- 26 sites in United States, Australia and 14 more
- Volunteers
- 500 people
- Sponsor
- Prof. Valérie Mc Lin
Hepatocellular Carcinoma
Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma
The purpose of this study is to assess the safety and tolerability of the investigational anticancer drug DCR-MYC. DCR-MYC is a novel synthetic double-stranded RNA in a stable lipid particle suspension that targets the oncogene…
- Trial name
- NCT02314052
- Testing
- DCR-MYC
- Where
- 6 sites in United States, Singapore and 1 more
- Volunteers
- 21 people
- Sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis
Biobank for Cholestatic Liver Diseases.
This study is a biobank of specimens and clinical data for use in current and future research to better understand the cholestatic liver diseases primary biliary cirrhosis/cholangitis (PBC) and primary sclerosing cholangitis…
- Conditions
- Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis, Cholangiocarcinoma, Liver Cancer
- Trial name
- NCT03445585
- Where
- United States
- Volunteers
- 9,150 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Gastric Cancer, Hepatocellular Carcinoma
Personalized DC Vaccine for Postoperative Cancer
The study is aimed to the test efficacy and safety of neoantigen-primed dendritic cell (DC) cell vaccine therapy for postoperative locally advanced gastric cancer, hepatocellular carcinoma, lung cancer and colorectal cancer, and…
- Conditions
- Gastric Cancer, Hepatocellular Carcinoma, Non-Small-Cell Lung Cancer, Colon Rectal Cancer
- Trial name
- NCT04147078
- Testing
- DC vaccine subcutaneous administration
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sichuan University
Adult Primary Hepatocellular Carcinoma, Localized Resectable Adult Primary Liver Cancer
Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
The purpose of this study is to determine if sorafenib (sorafenib tosylate) is a safe and effective treatment option for preventing liver cancer in high risk patients following liver transplantation.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT01624285
- Testing
- sorafenib tosylate, laboratory biomarker analysis
- Where
- 21 sites in United States
- Volunteers
- 73 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Non-metastatic Hepatocellular Carcinoma
Transarterial Chemoembolization Plus Hypofractionnated Radiotherapy vs. Surgery in Locally Advanced Hepatocellular Carcinoma: an IPTW Comparison
Patients with non-metastatic unresectable hepatocellular carcinoma
- Trial name
- TACE-hypoRT (NCT04823715)
- Testing
- TACE + hypofractionated EBRT, Surgical resection
- Where
- France
- Volunteers
- 163 people
- Sponsor
- Hospices Civils de Lyon
Advanced Cancers
Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab
The goal of this clinical research study is to find the highest tolerable dose of the combination of oxaliplatin and capecitabine with or without bevacizumab that can be given to patients with advanced cancer that has spread to…
- Trial name
- NCT01213238
- Testing
- Oxaliplatin, Capecitabine, Bevacizumab
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.